FLOVENT HFA Rx

Indications for FLOVENT HFA:

Maintenance treatment of asthma as prophylactic therapy. Asthma requiring systemic corticosteroid therapy, to reduce need for oral systemic corticosteroids.

Adult Dose for FLOVENT HFA:

Previously on bronchodilators alone: initially 88mcg twice daily; max 440mcg twice daily. Previously on inhaled corticosteroids: initially 88–220mcg twice daily; max 440mcg twice daily. Previously on oral corticosteroids (wean gradually): initially 440mcg twice daily; max 880mcg twice daily. Rinse mouth after use.

Children's Dose for FLOVENT HFA:

<4yrs: not recommended. 4–11yrs: 88mcg twice daily. Rinse mouth after use.

Pharmacological Class:

Steroid.

Contraindications:

Not for primary treatment of acute attack.

Warnings/Precautions:

Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually). Hepatic impairment (monitor). Transferring from oral corticosteroids: see literature. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Avoid ritonavir. Caution with potent CYP3A4 inhibitors (eg, ketoconazole).

Adverse Reactions:

Local effects (pharyngitis, nasal congestion/discharge, rhinitis, dysphonia, sinusitis, oral candidiasis), upper respiratory infection, headache, influenza, bronchospasm.

How Supplied:

Inhaler w. actuator (44mcg)—10.6g (120 inh); 110mcg, 220mcg—12g (120 inh)